BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Sosnik A, Chiappetta DA, Carcaboso ÁM. Drug delivery systems in HIV pharmacotherapy: What has been done and the challenges standing ahead. Journal of Controlled Release 2009;138:2-15. [DOI: 10.1016/j.jconrel.2009.05.007] [Cited by in Crossref: 80] [Cited by in F6Publishing: 72] [Article Influence: 6.2] [Reference Citation Analysis]
Number Citing Articles
1 Sharma P, Garg S. Pure drug and polymer based nanotechnologies for the improved solubility, stability, bioavailability and targeting of anti-HIV drugs. Adv Drug Deliv Rev 2010;62:491-502. [PMID: 19931328 DOI: 10.1016/j.addr.2009.11.019] [Cited by in Crossref: 114] [Cited by in F6Publishing: 99] [Article Influence: 9.5] [Reference Citation Analysis]
2 Ardestani MS, Fordoei AS, Abdoli A, Ahangari Cohan R, Bahramali G, Sadat SM, Siadat SD, Moloudian H, Nassiri Koopaei N, Bolhasani A, Rahimi P, Hekmat S, Davari M, Aghasadeghi MR. Nanosilver based anionic linear globular dendrimer with a special significant antiretroviral activity. J Mater Sci Mater Med 2015;26:179. [PMID: 25893388 DOI: 10.1007/s10856-015-5510-7] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 2.4] [Reference Citation Analysis]
3 Quijia CR, Bonatto CC, Silva LP, Andrade MA, Azevedo CS, Lasse Silva C, Vega M, de Santana JM, Bastos IMD, Carneiro MLB. Liposomes Composed by Membrane Lipid Extracts from Macrophage Cell Line as a Delivery of the Trypanocidal N,N'-Squaramide 17 towards Trypanosoma cruzi. Materials (Basel) 2020;13:E5505. [PMID: 33276688 DOI: 10.3390/ma13235505] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
4 Patel GV, Patel VB, Pathak A, Rajput SJ. Nanosuspension of efavirenz for improved oral bioavailability: formulation optimization, in vitro, in situ and in vivo evaluation. Drug Development and Industrial Pharmacy 2013;40:80-91. [DOI: 10.3109/03639045.2012.746362] [Cited by in Crossref: 44] [Cited by in F6Publishing: 40] [Article Influence: 4.9] [Reference Citation Analysis]
5 Sosnik A. Reversal of multidrug resistance by the inhibition of ATP-binding cassette pumps employing "Generally Recognized As Safe" (GRAS) nanopharmaceuticals: A review. Adv Drug Deliv Rev 2013;65:1828-51. [PMID: 24055628 DOI: 10.1016/j.addr.2013.09.002] [Cited by in Crossref: 73] [Cited by in F6Publishing: 68] [Article Influence: 8.1] [Reference Citation Analysis]
6 Mabrouk M, Chejara D, Mulla J, Badhe R, Choonara Y, Kumar P, du Toit L, Pillay V. Design of a novel crosslinked HEC-PAA porous hydrogel composite for dissolution rate and solubility enhancement of efavirenz. International Journal of Pharmaceutics 2015;490:429-37. [DOI: 10.1016/j.ijpharm.2015.05.082] [Cited by in Crossref: 19] [Cited by in F6Publishing: 15] [Article Influence: 2.7] [Reference Citation Analysis]
7 Corrêa JC, D'Arcy DM, Serra CH, Salgado HR. A critical review of properties of darunavir and analytical methods for its determination. Crit Rev Anal Chem 2014;44:16-22. [PMID: 25391211 DOI: 10.1080/10408347.2013.826573] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
8 Parboosing R, Maguire GE, Govender P, Kruger HG. Nanotechnology and the treatment of HIV infection. Viruses 2012;4:488-520. [PMID: 22590683 DOI: 10.3390/v4040488] [Cited by in Crossref: 76] [Cited by in F6Publishing: 59] [Article Influence: 7.6] [Reference Citation Analysis]
9 Chiappetta DA, Facorro G, de Celis ER, Sosnik A. Synergistic encapsulation of the anti-HIV agent efavirenz within mixed poloxamine/poloxamer polymeric micelles. Nanomedicine 2011;7:624-37. [PMID: 21371572 DOI: 10.1016/j.nano.2011.01.017] [Cited by in Crossref: 68] [Cited by in F6Publishing: 58] [Article Influence: 6.2] [Reference Citation Analysis]
10 Cuestas ML, Mathet VL, Oubiña JR, Sosnik A. Drug delivery systems and liver targeting for the improved pharmacotherapy of the hepatitis B virus (HBV) infection. Pharm Res 2010;27:1184-202. [PMID: 20333454 DOI: 10.1007/s11095-010-0112-z] [Cited by in Crossref: 21] [Cited by in F6Publishing: 15] [Article Influence: 1.8] [Reference Citation Analysis]
11 Agrati C, Marianecci C, Sennato S, Carafa M, Bordoni V, Cimini E, Tempestilli M, Pucillo LP, Turchi F, Martini F, Borioni G, Bordi F. Multicompartment vectors as novel drug delivery systems: selective activation of Tγδ lymphocytes after zoledronic acid delivery. Nanomedicine: Nanotechnology, Biology and Medicine 2011;7:153-61. [DOI: 10.1016/j.nano.2010.10.003] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 1.9] [Reference Citation Analysis]
12 Martin P, Giardiello M, Mcdonald TO, Smith D, Siccardi M, Rannard SP, Owen A. Augmented Inhibition of CYP3A4 in Human Primary Hepatocytes by Ritonavir Solid Drug Nanoparticles. Mol Pharmaceutics 2015;12:3556-68. [DOI: 10.1021/acs.molpharmaceut.5b00204] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.6] [Reference Citation Analysis]
13 Imperiale JC, Bevilacqua G, Rosa PDTVE, Sosnik A. Production of pure indinavir free base nanoparticles by a supercritical anti-solvent (SAS) method. Drug Development and Industrial Pharmacy 2014;40:1607-15. [DOI: 10.3109/03639045.2013.838581] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 1.3] [Reference Citation Analysis]
14 Kumar Sahoo S, Sankar Dash G, Biswal S, Kumar Biswal P, Chandra Senapati P. Fabrication and evaluation of self-nanoemulsifying oil formulations (SNEOFs) of Efavirenz. Journal of Dispersion Science and Technology 2019;40:464-75. [DOI: 10.1080/01932691.2018.1472008] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
15 Gagliardi M, Silvestri D, Cristallini C. Macromolecular composition and drug-loading effect on the delivery of paclitaxel and folic acid from acrylic matrices. Drug Delivery 2010;17:452-65. [DOI: 10.3109/10717544.2010.483253] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 0.9] [Reference Citation Analysis]
16 Menjoge AR, Navath RS, Asad A, Kannan S, Kim CJ, Romero R, Kannan RM. Transport and biodistribution of dendrimers across human fetal membranes: implications for intravaginal administration of dendrimer-drug conjugates. Biomaterials 2010;31:5007-21. [PMID: 20346497 DOI: 10.1016/j.biomaterials.2010.02.075] [Cited by in Crossref: 45] [Cited by in F6Publishing: 43] [Article Influence: 3.8] [Reference Citation Analysis]
17 Arca HÇ, Mosquera-giraldo LI, Dahal D, Taylor LS, Edgar KJ. Multidrug, Anti-HIV Amorphous Solid Dispersions: Nature and Mechanisms of Impacts of Drugs on Each Other’s Solution Concentrations. Mol Pharmaceutics 2017;14:3617-27. [DOI: 10.1021/acs.molpharmaceut.7b00203] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 3.6] [Reference Citation Analysis]
18 Hu M, Patel SK, Zhou T, Rohan LC. Drug transporters in tissues and cells relevant to sexual transmission of HIV: Implications for drug delivery. J Control Release 2015;219:681-96. [PMID: 26278511 DOI: 10.1016/j.jconrel.2015.08.018] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 2.6] [Reference Citation Analysis]
19 Chahibi Y. Molecular communication for drug delivery systems: A survey. Nano Communication Networks 2017;11:90-102. [DOI: 10.1016/j.nancom.2017.01.003] [Cited by in Crossref: 31] [Cited by in F6Publishing: 4] [Article Influence: 6.2] [Reference Citation Analysis]
20 Zidan AS, Spinks C, Fortunak J, Habib M, Khan MA. Near-infrared investigations of novel anti-HIV tenofovir liposomes. AAPS J 2010;12:202-14. [PMID: 20195931 DOI: 10.1208/s12248-010-9177-1] [Cited by in Crossref: 32] [Cited by in F6Publishing: 28] [Article Influence: 2.7] [Reference Citation Analysis]
21 Mainardes RM, Khalil NM, Gremião MPD. Intranasal delivery of zidovudine by PLA and PLA–PEG blend nanoparticles. International Journal of Pharmaceutics 2010;395:266-71. [DOI: 10.1016/j.ijpharm.2010.05.020] [Cited by in Crossref: 35] [Cited by in F6Publishing: 29] [Article Influence: 2.9] [Reference Citation Analysis]
22 Al-Ghananeem AM, Smith M, Coronel ML, Tran H. Advances in brain targeting and drug delivery of anti-HIV therapeutic agents. Expert Opin Drug Deliv 2013;10:973-85. [PMID: 23510097 DOI: 10.1517/17425247.2013.781999] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 1.2] [Reference Citation Analysis]
23 Sosnik A, Augustine R. Challenges in oral drug delivery of antiretrovirals and the innovative strategies to overcome them. Adv Drug Deliv Rev 2016;103:105-20. [PMID: 26772138 DOI: 10.1016/j.addr.2015.12.022] [Cited by in Crossref: 59] [Cited by in F6Publishing: 49] [Article Influence: 9.8] [Reference Citation Analysis]
24 Zidan AS, Rahman Z, Khan MA. Product and process understanding of a novel pediatric anti-HIV tenofovir niosomes with a high-pressure homogenizer. Eur J Pharm Sci 2011;44:93-102. [PMID: 21726640 DOI: 10.1016/j.ejps.2011.06.012] [Cited by in Crossref: 27] [Cited by in F6Publishing: 23] [Article Influence: 2.5] [Reference Citation Analysis]
25 de M Ribeiro LN, Fonseca BB. The role of pharmaceutical nanotechnology in the time of COVID-19 pandemic. Future Microbiol 2020;15:1571-82. [PMID: 33215525 DOI: 10.2217/fmb-2020-0118] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 2.5] [Reference Citation Analysis]
26 Li L, Zhang J, Li C, Chen L, Qiao R. A facile method for synthesizing water-soluble and superior sustained release anti-HIV prodrug SCs-d4T. Mater Sci Eng C Mater Biol Appl 2015;49:84-92. [PMID: 25686930 DOI: 10.1016/j.msec.2014.12.065] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
27 Tshweu L, Katata L, Kalombo L, Chiappetta DA, Hocht C, Sosnik A, Swai H. Enhanced oral bioavailability of the antiretroviral efavirenz encapsulated in poly(epsilon-caprolactone) nanoparticles by a spray-drying method. Nanomedicine (Lond) 2014;9:1821-33. [PMID: 24364871 DOI: 10.2217/nnm.13.167] [Cited by in Crossref: 32] [Cited by in F6Publishing: 28] [Article Influence: 3.6] [Reference Citation Analysis]
28 Kanmogne GD, Singh S, Roy U, Liu X, McMillan J, Gorantla S, Balkundi S, Smith N, Alnouti Y, Gautam N, Zhou Y, Poluektova L, Kabanov A, Bronich T, Gendelman HE. Mononuclear phagocyte intercellular crosstalk facilitates transmission of cell-targeted nanoformulated antiretroviral drugs to human brain endothelial cells. Int J Nanomedicine 2012;7:2373-88. [PMID: 22661891 DOI: 10.2147/IJN.S29454] [Cited by in Crossref: 42] [Cited by in F6Publishing: 25] [Article Influence: 4.2] [Reference Citation Analysis]
29 Seremeta KP, Höcht C, Taira C, Cortez Tornello PR, Abraham GA, Sosnik A. Didanosine-loaded poly(epsilon-caprolactone) microparticles by a coaxial electrohydrodynamic atomization (CEHDA) technique. J Mater Chem B 2015;3:102-11. [PMID: 32261930 DOI: 10.1039/c4tb00664j] [Cited by in Crossref: 11] [Cited by in F6Publishing: 2] [Article Influence: 1.4] [Reference Citation Analysis]
30 Kumar L, Verma S, Prasad DN, Bhardwaj A, Vaidya B, Jain AK. Nanotechnology: a magic bullet for HIV AIDS treatment. Artif Cells Nanomed Biotechnol 2015;43:71-86. [PMID: 24564348 DOI: 10.3109/21691401.2014.883400] [Cited by in Crossref: 32] [Cited by in F6Publishing: 23] [Article Influence: 4.0] [Reference Citation Analysis]
31 Chiappetta DA, Hocht C, Taira C, Sosnik A. Efavirenz-loaded polymeric micelles for pediatric anti-HIV pharmacotherapy with significantly higher oral bioavailability. Nanomedicine 2010;5:11-23. [DOI: 10.2217/nnm.09.90] [Cited by in Crossref: 114] [Cited by in F6Publishing: 96] [Article Influence: 9.5] [Reference Citation Analysis]
32 Blakney AK, Krogstad EA, Jiang YH, Woodrow KA. Delivery of multipurpose prevention drug combinations from electrospun nanofibers using composite microarchitectures. Int J Nanomedicine 2014;9:2967-78. [PMID: 24971008 DOI: 10.2147/IJN.S61664] [Cited by in Crossref: 49] [Cited by in F6Publishing: 23] [Article Influence: 6.1] [Reference Citation Analysis]
33 Giaretta M, Bianchin MD, Kanis LA, Contri RV, Külkamp-guerreiro IC. Development of Innovative Polymer-Based Matricial Nanostructures for Ritonavir Oral Administration. Journal of Nanomaterials 2019;2019:1-10. [DOI: 10.1155/2019/8619819] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
34 de Melo ACC, de Amorim IF, Cirqueira MDL, Martins FT. Toward Novel Solid-State Forms of the Anti-HIV Drug Efavirenz: From Low Screening Success to Cocrystals Engineering Strategies and Discovery of a New Polymorph. Crystal Growth & Design 2013;13:1558-69. [DOI: 10.1021/cg3018002] [Cited by in Crossref: 11] [Cited by in F6Publishing: 5] [Article Influence: 1.2] [Reference Citation Analysis]
35 Sosnik A, Seremeta KP, Imperiale JC, Chiappetta DA. Novel formulation and drug delivery strategies for the treatment of pediatric poverty-related diseases. Expert Opin Drug Deliv. 2012;9:303-323. [PMID: 22257003 DOI: 10.1517/17425247.2012.655268] [Cited by in Crossref: 28] [Cited by in F6Publishing: 25] [Article Influence: 2.8] [Reference Citation Analysis]
36 Bianchin MD, Prebianca G, Immich MF, Teixeira ML, Colombo M, Koester LS, Araújo BV, Poletto F, Külkamp-Guerreiro IC. Monoolein-based nanoparticles containing indinavir: a taste-masked drug delivery system. Drug Dev Ind Pharm 2021;47:83-91. [PMID: 33289591 DOI: 10.1080/03639045.2020.1862167] [Reference Citation Analysis]
37 de O. Porfírio L, Costa AA, Conceição RR, de O. Matos T, Almeida EDP, Sarmento VHV, Araújo AAS, de S. Nunes R, Lira AAM. Compatibility study of hydroxypropylmethylcellulose films containing zidovudine and lamivudine using thermal analysis and infrared spectroscopy. J Therm Anal Calorim 2015;120:817-28. [DOI: 10.1007/s10973-014-3938-5] [Cited by in Crossref: 10] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
38 Ruela Corrêa JC, D'Arcy DM, dos Reis Serra CH, Nunes Salgado HR. Darunavir: a critical review of its properties, use and drug interactions. Pharmacology 2012;90:102-9. [PMID: 22797653 DOI: 10.1159/000339862] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 1.9] [Reference Citation Analysis]
39 Jin Y, Xin R, Tong L, Du L, Li M. Combination Anti-HIV Therapy with the Self-Assemblies of an Asymmetric Bolaamphiphilic Zidovudine/Didanosine Prodrug. Mol Pharmaceutics 2011;8:867-76. [DOI: 10.1021/mp100457d] [Cited by in Crossref: 23] [Cited by in F6Publishing: 25] [Article Influence: 2.1] [Reference Citation Analysis]
40 Khalil NM, Carraro E, Cótica LF, Mainardes RM. Potential of polymeric nanoparticles in AIDS treatment and prevention. Expert Opin Drug Deliv 2011;8:95-112. [PMID: 21143001 DOI: 10.1517/17425247.2011.543673] [Cited by in Crossref: 22] [Cited by in F6Publishing: 19] [Article Influence: 1.8] [Reference Citation Analysis]
41 Xia X, Zhou C, Ballell L, Garcia-bennett AE. In vivo Enhancement in Bioavailability of Atazanavir in the Presence of Proton-Pump Inhibitors using Mesoporous Materials. ChemMedChem 2012;7:43-8. [DOI: 10.1002/cmdc.201100500] [Cited by in Crossref: 34] [Cited by in F6Publishing: 27] [Article Influence: 3.1] [Reference Citation Analysis]
42 Lembo D, Cavalli R. Nanoparticulate Delivery Systems for Antiviral Drugs. Antivir Chem Chemother 2010;21:53-70. [DOI: 10.3851/imp1684] [Cited by in Crossref: 97] [Cited by in F6Publishing: 18] [Article Influence: 8.1] [Reference Citation Analysis]
43 Imperiale JC, Nejamkin P, del Sole MJ, E. Lanusse C, Sosnik A. Novel protease inhibitor-loaded Nanoparticle-in-Microparticle Delivery System leads to a dramatic improvement of the oral pharmacokinetics in dogs. Biomaterials 2015;37:383-94. [DOI: 10.1016/j.biomaterials.2014.10.026] [Cited by in Crossref: 27] [Cited by in F6Publishing: 24] [Article Influence: 3.9] [Reference Citation Analysis]
44 Chiappetta DA, Hocht C, Opezzo JA, Sosnik A. Intranasal administration of antiretroviral-loaded micelles for anatomical targeting to the brain in HIV. Nanomedicine (Lond). 2013;8:223-237. [PMID: 23173734 DOI: 10.2217/nnm.12.104] [Cited by in Crossref: 61] [Cited by in F6Publishing: 56] [Article Influence: 6.1] [Reference Citation Analysis]
45 Mahajan K, Rojekar S, Desai D, Kulkarni S, Vavia P. Efavirenz Loaded Nanostructured Lipid Carriers for Efficient and Prolonged Viral Inhibition in HIV-Infected Macrophages. Pharm Sci 2021;27:418-32. [DOI: 10.34172/ps.2020.96] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
46 Chiappetta DA, Hocht C, Taira C, Sosnik A. Oral pharmacokinetics of the anti-HIV efavirenz encapsulated within polymeric micelles. Biomaterials 2011;32:2379-87. [DOI: 10.1016/j.biomaterials.2010.11.082] [Cited by in Crossref: 76] [Cited by in F6Publishing: 65] [Article Influence: 6.9] [Reference Citation Analysis]
47 Ravi PR, Vats R. Comparative pharmacokinetic evaluation of lopinavir and lopinavir-loaded solid lipid nanoparticles in hepatic impaired rat model. Journal of Pharmacy and Pharmacology 2017;69:823-33. [DOI: 10.1111/jphp.12716] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
48 Glisoni RJ, Sosnik A. Novel Poly(Ethylene Oxide)- b -Poly(Propylene Oxide) Copolymer-Glucose Conjugate by the Microwave-Assisted Ring Opening of a Sugar Lactone: Novel Poly(Ethylene Oxide)- b -Poly(Propylene Oxide) …. Macromol Biosci 2014;14:1639-51. [DOI: 10.1002/mabi.201400235] [Cited by in Crossref: 19] [Cited by in F6Publishing: 15] [Article Influence: 2.4] [Reference Citation Analysis]
49 Soni D, Bade AN, Gautam N, Herskovitz J, Ibrahim IM, Smith N, Wojtkiewicz MS, Dyavar Shetty BL, Alnouti Y, McMillan J, Gendelman HE, Edagwa BJ. Synthesis of a long acting nanoformulated emtricitabine ProTide. Biomaterials 2019;222:119441. [PMID: 31472458 DOI: 10.1016/j.biomaterials.2019.119441] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
50 Tolmacheva IA, Igosheva EV, Savinova OV, Boreko EI, Eremin VF, Grishko VV. Synthesis and evaluation of antiviral activities of triterpenic conjugates with 2-aminobutan-1-ol as potent microbicidal agents. Med Chem Res 2019;28:1648-60. [DOI: 10.1007/s00044-019-02401-w] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
51 Romero EL, Morilla MJ. Nanotechnological approaches against Chagas disease. Adv Drug Deliv Rev 2010;62:576-88. [PMID: 19941920 DOI: 10.1016/j.addr.2009.11.025] [Cited by in Crossref: 50] [Cited by in F6Publishing: 46] [Article Influence: 4.2] [Reference Citation Analysis]
52 Moretton MA, Taira C, Flor S, Bernabeu E, Lucangioli S, Höcht C, Chiappetta DA. Novel nelfinavir mesylate loaded d-α-tocopheryl polyethylene glycol 1000 succinate micelles for enhanced pediatric anti HIV therapy: In vitro characterization and in vivo evaluation. Colloids Surf B Biointerfaces 2014;123:302-10. [PMID: 25270729 DOI: 10.1016/j.colsurfb.2014.09.031] [Cited by in Crossref: 25] [Cited by in F6Publishing: 25] [Article Influence: 3.1] [Reference Citation Analysis]
53 Mahajan HS, Patil PH. Central composite design-based optimization of lopinavir vitamin E-TPGS micelle: In vitro characterization and in vivo pharmacokinetic study. Colloids Surf B Biointerfaces 2020;194:111149. [PMID: 32590243 DOI: 10.1016/j.colsurfb.2020.111149] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
54 Tiwari P, Kumar A, Prakash R. Electrochemical detection of azidothymidine on modified probes based on chitosan stabilised silver nanoparticles hybrid material. RSC Adv 2015;5:90089-97. [DOI: 10.1039/c5ra15908c] [Cited by in Crossref: 8] [Cited by in F6Publishing: 1] [Article Influence: 1.1] [Reference Citation Analysis]
55 Sathigari SK, Radhakrishnan VK, Davis VA, Parsons DL, Babu RJ. Amorphous-state characterization of efavirenz--polymer hot-melt extrusion systems for dissolution enhancement. J Pharm Sci 2012;101:3456-64. [PMID: 22437488 DOI: 10.1002/jps.23125] [Cited by in Crossref: 79] [Cited by in F6Publishing: 71] [Article Influence: 7.9] [Reference Citation Analysis]
56 Orkin C, Molina JM, Lombaard J, DeJesus E, Rodgers A, Kumar S, Martin E, Hanna G, Hwang C. Once-daily Doravirine in Human Immunodeficiency Virus Type 1-Infected, Antiretroviral-naive Adults: An Integrated Efficacy Analysis. Clin Infect Dis 2020;70:1344-52. [PMID: 31121015 DOI: 10.1093/cid/ciz424] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
57 Seremeta KP, Tur MIR, Pérez SM, Höcht C, Taira C, López Hernández OD, Sosnik A. Spray-dried didanosine-loaded polymeric particles for enhanced oral bioavailability. Colloids and Surfaces B: Biointerfaces 2014;123:515-23. [DOI: 10.1016/j.colsurfb.2014.09.055] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 2.0] [Reference Citation Analysis]
58 Trevaskis NL, Kaminskas LM, Porter CJH. From sewer to saviour — targeting the lymphatic system to promote drug exposure and activity. Nat Rev Drug Discov 2015;14:781-803. [DOI: 10.1038/nrd4608] [Cited by in Crossref: 279] [Cited by in F6Publishing: 266] [Article Influence: 39.9] [Reference Citation Analysis]
59 Kogawa AC, Mendonça JN, Lopes NP, Nunes Salgado HR. Stability-indicating thin-layer chromatographic method for determination of darunavir in complex darunavir–β-cyclodextrin in the presence of its degradation products. Anal Methods 2014;6:3689-93. [DOI: 10.1039/c4ay00248b] [Cited by in Crossref: 3] [Article Influence: 0.4] [Reference Citation Analysis]
60 Desai J, Thakkar H. Darunavir-Loaded Lipid Nanoparticles for Targeting to HIV Reservoirs. AAPS PharmSciTech 2018;19:648-60. [PMID: 28948564 DOI: 10.1208/s12249-017-0876-0] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 5.5] [Reference Citation Analysis]
61 Desai J, Thakkar H. Enhanced oral bioavailability and brain uptake of Darunavir using lipid nanoemulsion formulation. Colloids and Surfaces B: Biointerfaces 2019;175:143-9. [DOI: 10.1016/j.colsurfb.2018.11.057] [Cited by in Crossref: 20] [Cited by in F6Publishing: 9] [Article Influence: 6.7] [Reference Citation Analysis]
62 Avachat AM, Parpani SS. Formulation and development of bicontinuous nanostructured liquid crystalline particles of efavirenz. Colloids Surf B Biointerfaces 2015;126:87-97. [PMID: 25543986 DOI: 10.1016/j.colsurfb.2014.12.014] [Cited by in Crossref: 43] [Cited by in F6Publishing: 39] [Article Influence: 5.4] [Reference Citation Analysis]
63 Spinks CB, Zidan AS, Khan MA, Habib MJ, Faustino PJ. Pharmaceutical characterization of novel tenofovir liposomal formulations for enhanced oral drug delivery: in vitro pharmaceutics and Caco-2 permeability investigations. Clin Pharmacol 2017;9:29-38. [PMID: 28260952 DOI: 10.2147/CPAA.S119875] [Cited by in Crossref: 4] [Cited by in F6Publishing: 9] [Article Influence: 0.8] [Reference Citation Analysis]
64 Zainuddin R, Zaheer Z, Sangshetti JN, Momin M. Enhancement of oral bioavailability of anti-HIV drug rilpivirine HCl through nanosponge formulation. Drug Dev Ind Pharm 2017;43:2076-84. [PMID: 28845699 DOI: 10.1080/03639045.2017.1371732] [Cited by in Crossref: 19] [Cited by in F6Publishing: 14] [Article Influence: 3.8] [Reference Citation Analysis]
65 Chiappetta DA, Alvarez-lorenzo C, Rey-rico A, Taboada P, Concheiro A, Sosnik A. N-alkylation of poloxamines modulates micellar assembly and encapsulation and release of the antiretroviral efavirenz. European Journal of Pharmaceutics and Biopharmaceutics 2010;76:24-37. [DOI: 10.1016/j.ejpb.2010.05.007] [Cited by in Crossref: 59] [Cited by in F6Publishing: 51] [Article Influence: 4.9] [Reference Citation Analysis]
66 Gannon PJ, Akay-Espinoza C, Yee AC, Briand LA, Erickson MA, Gelman BB, Gao Y, Haughey NJ, Zink MC, Clements JE, Kim NS, Van De Walle G, Jensen BK, Vassar R, Pierce RC, Gill AJ, Kolson DL, Diehl JA, Mankowski JL, Jordan-Sciutto KL. HIV Protease Inhibitors Alter Amyloid Precursor Protein Processing via β-Site Amyloid Precursor Protein Cleaving Enzyme-1 Translational Up-Regulation. Am J Pathol 2017;187:91-109. [PMID: 27993242 DOI: 10.1016/j.ajpath.2016.09.006] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 3.6] [Reference Citation Analysis]
67 Hillaireau H, Dereuddre-Bosquet N, Skanji R, Bekkara-Aounallah F, Caron J, Lepêtre S, Argote S, Bauduin L, Yousfi R, Rogez-Kreuz C, Desmaële D, Rousseau B, Gref R, Andrieux K, Clayette P, Couvreur P. Anti-HIV efficacy and biodistribution of nucleoside reverse transcriptase inhibitors delivered as squalenoylated prodrug nanoassemblies. Biomaterials 2013;34:4831-8. [PMID: 23562054 DOI: 10.1016/j.biomaterials.2013.03.022] [Cited by in Crossref: 22] [Cited by in F6Publishing: 19] [Article Influence: 2.4] [Reference Citation Analysis]
68 Javan F, Vatanara A, Azadmanesh K, Nabi-meibodi M, shakouri M. Encapsulation of ritonavir in solid lipid nanoparticles: in-vitro anti-HIV-1 activity using lentiviral particles. Journal of Pharmacy and Pharmacology 2017;69:1002-9. [DOI: 10.1111/jphp.12737] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 3.0] [Reference Citation Analysis]
69 Chaudhari KR, Savjani JK, Savjani KT, Shah H. Improved Pharmaceutical Properties of Ritonavir through Co-crystallization Approach with Liquid Assisted Grinding Method. Drug Dev Ind Pharm 2022;:1-20. [PMID: 35156497 DOI: 10.1080/03639045.2022.2042553] [Reference Citation Analysis]
70 Witika BA, Stander JC, Smith VJ, Walker RB. Nano Co-Crystal Embedded Stimuli-Responsive Hydrogels: A Potential Approach to Treat HIV/AIDS. Pharmaceutics 2021;13:127. [PMID: 33498151 DOI: 10.3390/pharmaceutics13020127] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
71 Seremeta KP, Chiappetta DA, Sosnik A. Poly(ε-caprolactone), Eudragit® RS 100 and poly(ε-caprolactone)/Eudragit® RS 100 blend submicron particles for the sustained release of the antiretroviral efavirenz. Colloids Surf B Biointerfaces 2013;102:441-9. [PMID: 23010128 DOI: 10.1016/j.colsurfb.2012.06.038] [Cited by in Crossref: 68] [Cited by in F6Publishing: 57] [Article Influence: 6.8] [Reference Citation Analysis]
72 Nataraja RM, Fishman JR, Naseer A, Dodge J, Walters SM, Clarke SA, Haddad MJ. Percutaneous endoscopic gastrostomy placement in a human immunodeficiency virus-positive pediatric population leads to an increase in minor complications. J Laparoendosc Adv Surg Tech A. 2011;21:171-175. [PMID: 21194306 DOI: 10.1089/lap.2010.0139] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
73 Kogawa AC, Peltonen L, Antonio SG, Salgado HRN. Submission of Rifaximin to Different Techniques: Characterization, Solubility Study, and Microbiological Evaluation. AAPS PharmSciTech 2019;20:125. [PMID: 30805802 DOI: 10.1208/s12249-019-1329-8] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 3.3] [Reference Citation Analysis]
74 Singh Chauhan P, Abutbul Ionita I, Moshe Halamish H, Sosnik A, Danino D. Multidomain drug delivery systems of β-casein micelles for the local oral co-administration of antiretroviral combinations. J Colloid Interface Sci 2021;592:156-66. [PMID: 33652169 DOI: 10.1016/j.jcis.2020.12.021] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
75 Augustine R, Ashkenazi DL, Arzi RS, Zlobin V, Shofti R, Sosnik A. Nanoparticle-in-microparticle oral drug delivery system of a clinically relevant darunavir/ritonavir antiretroviral combination. Acta Biomater 2018;74:344-59. [PMID: 29723705 DOI: 10.1016/j.actbio.2018.04.045] [Cited by in Crossref: 34] [Cited by in F6Publishing: 27] [Article Influence: 8.5] [Reference Citation Analysis]
76 Desai J, Thakkar H. Effect of particle size on oral bioavailability of darunavir-loaded solid lipid nanoparticles. Journal of Microencapsulation 2016;33:669-78. [DOI: 10.1080/02652048.2016.1245363] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 2.3] [Reference Citation Analysis]